These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 24085583)
21. The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results. Guo M; Gong Y; Wang J; Dawlett M; Patel S; Liu P; Bevers TB; Sneige N Cancer Cytopathol; 2013 Feb; 121(2):79-85. PubMed ID: 23225501 [TBL] [Abstract][Full Text] [Related]
22. Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a result not to be ignored. Barreth D; Schepansky A; Capstick V; Johnson G; Steed H; Faught W J Obstet Gynaecol Can; 2006 Dec; 28(12):1095-1098. PubMed ID: 17169233 [TBL] [Abstract][Full Text] [Related]
23. Does the interval between papanicolaou tests influence the quality of cytology? Jeronimo J; Khan MJ; Schiffman M; Solomon D; Cancer; 2005 Jun; 105(3):133-8. PubMed ID: 15822121 [TBL] [Abstract][Full Text] [Related]
24. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg. Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516 [TBL] [Abstract][Full Text] [Related]
25. Prevalence of high grade squamous intraepithelial lesions (HSIL) and invasive cervical cancer in patients with atypical squamous cells of undetermined significance (ASCUS) from cervical pap smears. Limpvanuspong B; Tangjitgamol S; Manusirivithaya S; Khunnarong J; Thavaramara T; Leelahakorn S Southeast Asian J Trop Med Public Health; 2008 Jul; 39(4):737-44. PubMed ID: 19058614 [TBL] [Abstract][Full Text] [Related]
26. Quality metrics in cervical cytopathology: A single institutional study. Senthil Kumar D; Ravikumar G Cytopathology; 2022 Mar; 33(2):230-235. PubMed ID: 34854153 [TBL] [Abstract][Full Text] [Related]
27. Cervical cancer screening by cytology and the burden of epithelial abnormalities in low resource settings: a tertiary-center 42-year study. Ezzelarab S; El-Husseiny A; Nasreldin M; Ali R; Nabhan A; BMC Womens Health; 2024 Jul; 24(1):405. PubMed ID: 39020330 [TBL] [Abstract][Full Text] [Related]
28. Low-grade squamous intraepithelial lesion/cannot exclude high-grade squamous intraepithelial lesion (LSIL-H) is a unique category of cytologic abnormality associated with distinctive HPV and histopathologic CIN 2+ detection rates. Barron S; Li Z; Austin RM; Zhao C Am J Clin Pathol; 2014 Feb; 141(2):239-46. PubMed ID: 24436272 [TBL] [Abstract][Full Text] [Related]
29. Low-grade pap smears containing occasional high-grade cells as a predictor of high-grade dysplasia. Power P; Gregoire J; Duggan M; Nation J J Obstet Gynaecol Can; 2006 Oct; 28(10):884-887. PubMed ID: 17140504 [TBL] [Abstract][Full Text] [Related]
30. [Evaluation of cytological screening for cancers and precancerous lesions of the cervix]. Boman F; Duhamel A; Trinh QD; Deken V; Leroy JL; Beuscart R Bull Cancer; 2003 Jul; 90(7):643-7. PubMed ID: 12957806 [TBL] [Abstract][Full Text] [Related]
31. [Significance of p16/Ki-67 double immunocytochemical staining in cervical cytology ASCUS, LSIL, and ASC-H]. Wu Y; Zhao J; Hu J; Wu XW; Zhu LR Zhonghua Fu Chan Ke Za Zhi; 2017 Nov; 52(11):734-739. PubMed ID: 29179267 [No Abstract] [Full Text] [Related]
32. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309 [TBL] [Abstract][Full Text] [Related]
33. Role of Pap Test terminology and age in the detection of carcinoma invasive and carcinoma in situ in medically underserved California women. Howell LP; Tabnak F; Tudury AJ; Stoodt G Diagn Cytopathol; 2004 Apr; 30(4):227-34. PubMed ID: 15048955 [TBL] [Abstract][Full Text] [Related]
34. Utility of p16 Immunohistochemistry in Evaluating Negative Cervical Biopsies Following High-risk Pap Test Results. Shain AF; Kwok S; Folkins AK; Kong CS Am J Surg Pathol; 2018 Jan; 42(1):69-75. PubMed ID: 29112019 [TBL] [Abstract][Full Text] [Related]
35. Managing atypical squamous cells of undetermined significance in Papanicolaou smears. Morin C; Bairati I; Bouchard C; Fortier M; Roy M; Moore L; Meisels A J Reprod Med; 2001 Sep; 46(9):799-805. PubMed ID: 11584480 [TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic. Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169 [TBL] [Abstract][Full Text] [Related]
37. The Incidence and Clinical Significance of Atypical Glandular Cells of Undetermined Significance on Cervical Pap Smears. Al-Rayyan E; Rashed M; Maaita M; Qudah S; Taso O; Haddadin W Gulf J Oncolog; 2019 May; 1(30):52-56. PubMed ID: 31242982 [TBL] [Abstract][Full Text] [Related]
38. Improved abnormal Pap smear triage using cervical cancer biomarkers. Killeen JL; Dye T; Grace C; Hiraoka M J Low Genit Tract Dis; 2014 Jan; 18(1):1-7. PubMed ID: 23760145 [TBL] [Abstract][Full Text] [Related]
40. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. Arbyn M; Buntinx F; Van Ranst M; Paraskevaidis E; Martin-Hirsch P; Dillner J J Natl Cancer Inst; 2004 Feb; 96(4):280-93. PubMed ID: 14970277 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]